Talha K Burki. Show Affiliations »
Abstract
Entities: Gene
Mesh: See more » Administrative Personnel/legislation & jurisprudenceAntigens, CD19/economicsAntigens, CD19/therapeutic useClinical Trials as TopicCost of IllnessCytokine Release Syndrome/chemically inducedCytokine Release Syndrome/economicsCytokine Release Syndrome/epidemiologyDeveloping Countries/economicsHealth Care Costs/statistics & numerical dataHematopoietic Stem Cell Transplantation/economicsHematopoietic Stem Cell Transplantation/statistics & numerical dataHumansImmunotherapy, Adoptive/economicsImmunotherapy, Adoptive/statistics & numerical dataIndia/epidemiologyLymphoma, B-Cell/drug therapyLymphoma, B-Cell/immunologyMultiple Myeloma/drug therapyMultiple Myeloma/immunologyPoland/epidemiologyRemission Induction/methodsTreatment Outcome
Substances: See more » Antigens, CD19axicabtagene ciloleucel
Year: 2021 PMID: 33770482 DOI: 10.1016/S2352-3026(21)00068-5
Source DB: PubMed Journal: Lancet Haematol ISSN: 2352-3026 Impact factor: 18.959